Edwards Lifesciences (NYSE:EW) Sets New 52-Week High – Here’s Why

Posted by Geri Gentry on May 26th, 2026

Shares of Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as $87.93 and last traded at $87.87, with a volume of 2539265 shares changing hands. The stock had previously closed at $85.78.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. UBS Group restated a “neutral” rating and set a $94.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Robert W. Baird lifted their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. The Goldman Sachs Group restated a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $95.65.

Read Our Latest Analysis on EW

Edwards Lifesciences Trading Up 2.1%

The firm’s 50-day moving average price is $81.45 and its 200 day moving average price is $82.90. The company has a market cap of $50.43 billion, a price-to-earnings ratio of 46.59, a P/E/G ratio of 2.15 and a beta of 0.87. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,816,861.34. The trade was a 2.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 106,684 shares of company stock valued at $8,811,739 in the last 90 days. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Hanson & Doremus Investment Management acquired a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $25,000. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $25,000. MV Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth approximately $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $27,000. 79.46% of the stock is owned by institutional investors.

About Edwards Lifesciences

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.